Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2670-2673

  Lin, Kai ^a   Karwowska, Sylwia ^a   Lam, Eric ^b   Limoli, Kay ^b   Evans, Thomas G ^a   Avila, Claudio ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TELBIVUDINE;

ARTICLE; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SUPERINFECTION; VIRUS ISOLATION; WILD TYPE;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; PYRIMIDINONES;

EID: 77952647304     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01703-09     Document Type: Article

References (16)

1. Alter, M. J. 2006. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44:S6-S9. (Pubitemid 43053865)
2. Benhamou, Y., V. Thibault, P. Vig, V. Calvez, A. G. Marcelin, M. H. Fievet, G. Currie, C. G. Chang, L. Biao, S. Xiong, C. Brosgart, and T. Poynard. 2006. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol. 44:62-67.
3. Domaoal, R. A., M. McMahon, C. L. Thio, C. M. Bailey, J. Tirado-Rives, A. Obikhod, M. Detorio, K. L. Rapp, R. F. Siliciano, R. F. Schinazi, and K. S. Anderson. 2008. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 283:5452-5459.
4. Dore, G. J., D. A. Cooper, C. Barrett, L. E. Goh, B. Thakrar, and M. Atkins. 1999. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J. Infect. Dis. 180: 607-613.
5. Dore, G. J., D. A. Cooper, A. L. Pozniak, E. DeJesus, L. Zhong, M. D. Miller, B. Lu, and A. K. Cheng. 2004. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189:1185-1192.
6. Gish, R. G., H. Trinh, N. Leung, F. K. Chan, M. W. Fried, T. L. Wright, C. Wang, J. Anderson, E. Mondou, A. Snow, J. Sorbel, F. Rousseau, and L. Corey. 2005. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J. Hepatol. 43:60-66.
7. Lin, P. F., B. Nowicka-Sans, B. Terry, S. Zhang, C. Wang, L. Fan, I. Dicker, V. Gali, H. Higley, N. Parkin, D. Tenney, M. Krystal, and R. Colonno. 2008. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob. Agents Chemother. 52:1759-1767.
8. Low, E., A. Cox, M. Atkins, and M. Nelson. 2009. Telbivudine has activity against HIV-1. AIDS 23:546-547.
9. McMahon, M. A., B. L. Jilek, T. P. Brennan, L. Shen, Y. Zhou, M. Wind-Rotolo, S. Xing, S. Bhat, B. Hale, R. Hegarty, C. R. Chong, J. O. Liu, R. F. Siliciano, and C. L. Thio. 2007. The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356:2614-2621.
10. Milazzo, L., I. Caramma, A. Lai, M. Violin, C. De Maddalena, M. Cesari, M. Galli, and C. Balotta. 2009. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir. Ther. 14:869-872.
11. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
12. Sheldon, J. A., A. Corral, B. Rodes, S. Mauss, J. Rockstroh, F. Berger, C. Schwarze-Zander, and V. Soriano. 2005. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 19:2036-2038.
13. Soriano, V., M. Puoti, M. Peters, Y. Benhamou, M. Sulkowski, F. Zoulim, S. Mauss, and J. Rockstroh. 2008. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22:1399-1410.
14. Standring, D. N., E. G. Bridges, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, E. Cretton-Scott, R. F. Schinazi, M. Myers, M. L. Bryant, and J. P. Sommadossi. 2001. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12(Suppl 1):119-129.
15. Thio, C. L. 2009. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49:S138-S145.
16. Wolters, L. M., H. G. Niesters, B. E. Hansen, M. E. van der Ende, F. P. Kroon, C. Richter, K. Brinkman, P. L. Meenhorst, and R. A. de Man. 2002. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J. Clin. Virol. 24:173-181.